Related Experiment Video
Updated: Feb 13, 2026

A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies
Published on: November 7, 2015
The role of tumor microenvironment in resistance to anti-angiogenic therapy
Shaolin Ma1,2, Sunila Pradeep1, Wei Hu1
1Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract:
Anti-angiogenic therapy has been demonstrated to increase progression-free survival in patients with many different solid cancers. Unfortunately, the benefit in overall survival is modest and the rapid emergence of drug resistance is a significant clinical problem. Over the last decade, several mechanisms have been identified to decipher the emergence of resistance. There is a multitude of changes within the tumor microenvironment (TME) in response to anti-angiogenic therapy that offers new therapeutic opportunities. In this review, we compile results from contemporary studies related to adaptive changes in the TME in the development of resistance to anti-angiogenic therapy. These include preclinical models of emerging resistance, dynamic changes in hypoxia signaling and stromal cells during treatment, and novel strategies to overcome resistance by targeting the TME.
Insights
Anti-angiogenic therapy improves progression-free survival but faces challenges with modest overall survival benefits and rapid drug resistance. Targeting the tumor microenvironment (TME) offers new strategies to overcome resistance in solid cancers.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Anti-angiogenic therapy shows promise in extending progression-free survival for solid tumors.
- Limited overall survival benefits and the rapid development of drug resistance remain significant clinical hurdles.
- The tumor microenvironment (TME) undergoes adaptive changes in response to anti-angiogenic treatments.
Purpose of the Study:
- To review adaptive changes in the TME contributing to anti-angiogenic therapy resistance.
- To explore novel therapeutic strategies targeting the TME to overcome resistance.
- To synthesize findings from preclinical models and clinical studies on TME-mediated resistance.
Main Methods:
- Comprehensive literature review of contemporary studies on anti-angiogenic therapy resistance.
- Analysis of preclinical models investigating mechanisms of resistance.
- Examination of dynamic changes in hypoxia signaling and stromal cells during treatment.
Main Results:
- Identified multiple mechanisms of resistance emerging from adaptive TME changes.
- Highlighted the role of hypoxia signaling and stromal cell dynamics in treatment failure.
- Demonstrated the potential of TME-targeting strategies in preclinical settings.
Conclusions:
- Adaptive changes in the TME are critical drivers of resistance to anti-angiogenic therapy.
- Targeting the TME presents a promising avenue for enhancing therapeutic efficacy and overcoming resistance.
- Further research into TME modulation is essential for improving patient outcomes in solid cancers.
More Related Videos
Related Concept Videos
The Tumor Microenvironment
Resistivity
Resistance
Gene Therapy
Equivalent Resistance
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...

